The only up-to-date definitive reference source onhemophilia This book is an invaluable resource that provides an overview ofall aspects of the care of patients with haemophilia. Covering how to assess both bleeding children and adults,Haemophilia A and B, molecular basis of the disease, the role offactors in coagulation, epidemiology, pharmacokinetics, andtreatment of inhibitors. There will also be a section onmusculoskeletal aspects of haemophilia as well as newerdevelopments such as gene therapy and rare bleedingdisorders. Textbook of Hemophilia is ideal for: Trainees and residents in hematology Hematologists in practice Specialists working in thrombosis and hemostasis as well astransfusion medicine Why Buy This Book? The only up-to-date definitive reference source onhemophilia Essential for all those managing hemophilia patients Detailed guidance on assessment, diagnosis, management andtreatment Advice for everyday clinical questions Edited by three of the world’s leading experts onhemophilia

For thousands of years boys known as "bleeders" faced an early, painful death from hemophilia. Dubbed "the Royal Disease" because of its identification with Queen Victoria, the world's most renowned carrier, hemophilia is a genetic disease whose sufferers had little recourse until the mid-twentieth century. In the first book to chronicle the emergence and transformation of the hemophilia community, Susan Resnik sets her story within our national political landscape—where the disease is also a social, psychological, and economic experience. Blood Saga includes many players and domains: men with hemophilia and their families, medical personnel, science researchers, and the author herself, who was Director of Education of the National Hemophilia Foundation in the early 1980s. At that time the "miracle treatment" of freeze-dried pooled plasma blood products enabled men with hemophilia to lead full, normal lives. Then the AIDS virus infiltrated the treatment system and over fifty percent of the hemophilia community became HIV-positive. But rather than collapsing, this community refocused its priorities, extended its reach, and helped shape blood safety policies to prevent further tragedy. The hemophilia community includes people from every socioeconomic and ethnic group, and Resnik's narrative and use of oral histories never lose touch with those affected by the disease. Her extensive informant interviewing allows much of this social history to be told by participants on all levels: parents, wives, nurses, doctors, government agency directors, health care providers, and many others. Gene insertion therapy now holds the promise of a cure for hemophilia in the near future. Scientific breakthroughs inevitably become intertwined with the industry and academic medical centers that govern the national health care system. And in that system, says Resnik, costs and safety are sometimes contending issues. She makes clear that the lessons learned in Blood Saga apply to all of us.

Hemophilia and Von Willebrand Disease: Factor VIII and Von Willebrand Factor serves as a must-have reference on the important role these essential blood-clotting proteins play in research and clinical medicine. Clinicians and researchers face the daily challenge of staying current on the vast amounts of research that is now generated. The reference to Janus in the title refers to the two roles of the Factor VIII/Von Willebrand Factor Complex: initiation of coagulation and propagation of clot formation. The complex prevents bleeding in hemophilia and Von Willebrand disease but also augments arterial and venous thrombosis. Presents one source of information on Hemophilia and Von Willebrand Disease, as well as Factor VIII and Von Willebrand Factor, eliminating the search through hundreds of journal articles Combines the multi-disciplinary research that is generated from Factor VIII/Von Willebrand Factor – hematology, drug discovery, genetics, cell biology, and oncology Delves into unanswered questions and future directions of this important blood-clotting complex

Linked by Blood: Hemophilia and AIDS recounts the factors responsible for the widespread infection of people with hemophilia by Human Immunodeficiency Virus (HIV)-contaminated blood and offers a prescription for addressing the challenges of future viral epidemics. The book describes the impact of AIDS on people with hemophilia, their families, and caregivers. The collection, processing, and distribution of blood in the early years of the HIV epidemic are described, including the failure of regulatory agencies to promulgate effective rules to safeguard the blood supply. The contributions of individuals and organizations that mitigated the epidemic are recognized. Linked by Blood presents recommendations for addressing the myriad medical, social, and economic challenges posed by blood-borne viral infections (AIDS, Ebola, MERS) that periodically sweep through large segments of our population. Addresses the challenges of future viral epidemics Promotes understanding of the risks and benefits of blood transfusion Demystifies HIV/AIDS by explaining how the virus causes disease and is detected and treated Covers the factors that led to contamination of the blood supply and contributed to the AIDS epidemic Provides background information on hemophilia: who is affected, why they bleed, how it is treated, and what complications can occur Discusses the role of regulatory agencies in protecting the blood supply and ensuring the safety of blood and blood products Features new proposals to enhance blood product safety and regulate the prices of blood, drugs, and devices that are essential for human health

Hemophilia is a genetic disease that impairs the normal process of blood clotting and results in uncontrolled external and internal bleeding. The reader of this book will learn how a diagnosis of hemophilia is made by blood clot­ting tests and measurements of clotting factor levels in blood. The book describes how hemophilia A and B are caused by mutations in genes that encode clotting factor VIII and clotting factor IX, respectively, both of which are carried on the X chromosome. As a result, almost all children born with hemophilia A and B are boys. Hemophilia C is caused by mutations in the clotting factor XI gene on chromosome 4, and occurs in males and females with equal frequency. The author details the use of factor replacement therapy to treat hemophilia, and evaluates the prospects for curing hemophilia through gene therapy and genome editing.

This book describes in detail the clinical presentation, diagnosis, and management of a wide range of congenital bleeding disorders. It will assist readers in overcoming the significant challenges involved in clinical and laboratory diagnosis and in providing effective clinical care that makes optimal use of new products, including recombinant factor concentrate. The coverage ranges from hemophilia A and B and von Willebrand disease to rare bleeding disorders such as congenital factor V, factor X, factor XI, and factor XIII deficiency and inherited platelet function disorders. The exceptional attention to rarer conditions is of particular importance given the considerable risk of overlooking them during diagnosis, with potential consequences for disease-related morbidity and mortality. The authors are acknowledged specialists in the field from across the world who have particular expertise in the disorder that they discuss. The book will be of value to hematologists, oncologists, pediatricians, laboratory specialists and technicians, general physicians, and trainees.

A parenting book covering medical, consumer, emotional and practical child-rearing aspects of raising a child with hemophilia.